115 related articles for article (PubMed ID: 26965851)
1. Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes.
Asciutto G; Wigren M; Fredrikson GN; Mattisson IY; Grönberg C; Alm R; Björkbacka H; Dias NV; Edsfeldt A; Gonçalves I; Nilsson J
Stroke; 2016 Apr; 47(4):1140-3. PubMed ID: 26965851
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events.
Fredrikson GN; Schiopu A; Berglund G; Alm R; Shah PK; Nilsson J
Atherosclerosis; 2007 Oct; 194(2):e188-92. PubMed ID: 17214995
[TBL] [Abstract][Full Text] [Related]
3. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
[TBL] [Abstract][Full Text] [Related]
4. Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.
Fagerberg B; Prahl Gullberg U; Alm R; Nilsson J; Fredrikson GN
PLoS One; 2015; 10(3):e0120744. PubMed ID: 25768285
[TBL] [Abstract][Full Text] [Related]
5. Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque.
Imai M; Kawamura M; Kochi I; Matsuoka T; Kihara S; Yamamoto H
J Atheroscler Thromb; 2021 Oct; 28(10):1025-1034. PubMed ID: 33191364
[TBL] [Abstract][Full Text] [Related]
6. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
[TBL] [Abstract][Full Text] [Related]
7. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus.
Svenungsson E; Engelbertsen D; Wigren M; Gustafsson JT; Gunnarsson I; Elvin K; Jensen-Urstad K; Fredrikson GN; Nilsson J
Clin Exp Immunol; 2015 Sep; 181(3):417-26. PubMed ID: 25959453
[TBL] [Abstract][Full Text] [Related]
8. Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment.
Yamamoto H; Kawamura M; Kochi I; Imai M; Murata Y; Suzuki T; Chen Y; Hashimoto K; Kihara S
J Atheroscler Thromb; 2019 Oct; 26(10):931-943. PubMed ID: 30867375
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage.
Pruijm M; Schmidtko J; Aho A; Pagano S; Roux-Lombard P; Teta D; Burnier M; Vuilleumier N
Ther Apher Dial; 2012 Dec; 16(6):588-94. PubMed ID: 23190520
[TBL] [Abstract][Full Text] [Related]
10. Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events.
Björkbacka H; Alm R; Persson M; Hedblad B; Nilsson J; Fredrikson GN
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):765-71. PubMed ID: 26916732
[TBL] [Abstract][Full Text] [Related]
11. Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions.
Gonçalves I; Nitulescu M; Ares MP; Fredrikson GN; Jansson B; Li ZC; Nilsson J
Atherosclerosis; 2009 Jul; 205(1):96-100. PubMed ID: 19150065
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men.
Sjögren P; Fredrikson GN; Rosell M; de Faire U; Hamsten A; Nilsson J; Hellenius ML; Fisher RM
Metabolism; 2008 Mar; 57(3):362-6. PubMed ID: 18249208
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques.
Grufman H; Gonçalves I; Edsfeldt A; Nitulescu M; Persson A; Nilsson M; Nilsson J
J Intern Med; 2014 Feb; 275(2):127-33. PubMed ID: 24010553
[TBL] [Abstract][Full Text] [Related]
14. Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.
Engelbertsen D; Vallejo J; Quách TD; Fredrikson GN; Alm R; Hedblad B; Björkbacka H; Rothstein TL; Nilsson J; Bengtsson E
J Immunol; 2015 Oct; 195(7):3020-5. PubMed ID: 26290603
[TBL] [Abstract][Full Text] [Related]
15. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.
Virella G; Wilson K; Elkes J; Hammad SM; Rajab HA; Li Y; Chassereau C; Huang Y; Lopes-Virella M
Clin Immunol; 2018 Feb; 187():1-9. PubMed ID: 28689783
[TBL] [Abstract][Full Text] [Related]
16. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease.
Fredrikson GN; Hedblad B; Berglund G; Alm R; Nilsson JA; Schiopu A; Shah PK; Nilsson J
Stroke; 2007 May; 38(5):1495-500. PubMed ID: 17363723
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
18. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes.
Fredrikson GN; Anand DV; Hopkins D; Corder R; Alm R; Bengtsson E; Shah PK; Lahiri A; Nilsson J
Diabetologia; 2009 Jul; 52(7):1426-33. PubMed ID: 19448981
[TBL] [Abstract][Full Text] [Related]
19. Increased aldehyde-modification of collagen type IV in symptomatic plaques--a possible cause of endothelial dysfunction.
Dunér P; Gonçalves I; Grufman H; Edsfeldt A; To F; Nitulescu M; Nilsson J; Bengtsson E
Atherosclerosis; 2015 May; 240(1):26-32. PubMed ID: 25746374
[TBL] [Abstract][Full Text] [Related]
20. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.
McLeod O; Silveira A; Fredrikson GN; Gertow K; Baldassarre D; Veglia F; Sennblad B; Strawbridge RJ; Larsson M; Leander K; Gigante B; Kauhanen J; Rauramaa R; Smit AJ; Mannarino E; Giral P; Humphries SE; Tremoli E; de Faire U; Ohrvik J; Nilsson J; Hamsten A
Atherosclerosis; 2014 Jan; 232(1):242-8. PubMed ID: 24401246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
